Answers are grounded in this paper and cite their sources.
Instillation with Bacillus Calmette‐Guérin (BCG) is recommended as adjuvant treatment in non‐muscle invasive bladder cancer. It is well recognized that intravesical immunotherapy with BCG might cause side effects, commonly affecting the patient´s well‐being. To enable detection of any symptoms important for decisions on the further treatment it is important to keep records of the patient's bladder and voiding status before and during the treatment. Management of side effects may be required and occasionally instillation must be postponed or stopped. We aimed to develop a validated instrument to capture and grade symptoms in patients with non‐muscle invasive bladder cancer undergoing intravesical instillation therapy with BCG. Intravesical immunotherapy with BCG commonly results in side effects, that negatively affect the patient´s well‐being. There is currently no validated instrument for follow‐up of patients during long‐term intravesical instillation treatment. Many individual reports as well as guideline recommendations, describe that intravesical instillation treatment with BCG can cause local or systemic side effects of both mild and severe character. Recommendations on how to treat various side effects exist and it is emphasized that patients with bladder cancers need continuous support during the instillation treatment. There is, however, shortage of information about how to best detect the patient's symptoms to give optimal support. A qualitative study design was used to gain knowledge about patients' symptoms and side effects during the instillation treatment. We used a previous study protocol to study questions, answer options and open‐ended questions. In Sweden, different unvalidated forms have been applied to detect symptoms during instillation therapy. Those symptom forms were collected and analyzed. Dialogues were held with patients and representatives from various professions with knowledge in the field. All qualitative data were structured and categorized and subsequently used for the construction of a bladder instillation therapy form. The face‐to‐face validity method was used in the process. We developed and validated an instrument: Bladder Instillation Therapy Form (BITF), for use by patients who receive intravesical instillations with BCG. The form separately considered local and systemic symptoms. The answer options were adapted to the question and formulated to enable follow‐up of the patient's symptoms. An instrument, BITF, was developed and validated for assessment of symptoms during intravesical instillation BCG therapy. BITF was designed to provide baseline information at the start of treatment as well as before each instillation. BITF can also be used for future research. The BITF enables assessment of side‐effects during intravesical BCG instillation therapy and accordingly appropriate measures can be taken to support the patient throughout the treatment period. The BITF instrument will improve patient care as well as laying ground for future research.
No takes yet. Share an insight, caveat, or question.
Danielsson et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: